Mark Yancey

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Luis Feo Bernabé, Roberta Portela, Sandra Nguyen et al. · BMC Veterinary Research · 2013 · 88 citations · Full text

Quantitative liquid chromatographic–tandem mass spectrometric determination of reserpine in FVB/N mouse plasma using a “chelating” agent (disodium EDTA) for releasing protein-bound analytes during 96-well liquid–liquid extraction

Jing Ke, Mark Yancey, Sheng Zhang et al. · Journal of Chromatography B Biomedical Sciences and Applications · 2000 · 51 citations

Disodium Edta, Biochemistry, Medicine +12

Rapid and prolonged distribution of tulathromycin into lung homogenate and pulmonary epithelial lining fluid of Holstein calves following a single subcutaneous administration of 2.5 mg/kg body weight.

Steven R. Cox, C. McLaughlin, A. Fielder et al. · ˜The œjournal of applied research in veterinary medicine · 2010 · 43 citations

Healthy Holstein, Pathology, Education +16

Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors

Mark Yancey, Dawn A. Merritt, S. P. LESMAN et al. · Journal of Veterinary Pharmacology and Therapeutics · 2010 · 42 citations

A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

Giuseppe Giaccone, Aditya Rajan, Ronan J. Kelly et al. · Journal of Clinical Oncology · 2010 · 37 citations

Tumor Biology, Oncology, Solid Tumors +12